Program
Atorvastatin
Also written as “atorvastatin”, “Atorvastatin 20 mg” and “Comparator: atorvastatin”.
Its studies are mostly in Hypercholesterolemia · Dyslipidemias · Hyperlipidemias · Diabetes Mellitus, Type 2 · Cardiovascular Diseases, led by 22 companies.
Drug pageAtorvastatin: every studyMany companies study it; this page follows only the 105 they lead. All 640 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatrisits history only | 290 open or running | phase 4since Aug 30, 2005 | Aug 25, 2005 | none ahead |
| Organon | 200 open or running | phase 4since Apr 1, 2008 | Sep 23, 2004 | none ahead |
| Pfizerits history only | 160 open or running | phase 4since Sep 6, 2005 | Aug 22, 2005 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 60 open or running | phase 4since Nov 16, 2009 | Nov 16, 2009 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 60 open or running | phase 1since Jul 18, 2012 | Jul 18, 2012 | none ahead |
| GlaxoSmithKlineits history only | 60 open or running | phase 3since Dec 15, 2011 | Dec 11, 2006 | none ahead |
| Astellas Pharmaits history only | 30 open or running | phase 4since Dec 5, 2006 | Dec 5, 2006 | none ahead |
| Daiichi Sankyoits history only | 30 open or running | phase 4since Sep 16, 2008 | Sep 16, 2008 | none ahead |
| Midas Pharmaits history only | 20 open or running | phase 1since Jan 23, 2020 | Jan 23, 2020 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | phase 1since Dec 20, 2011 | Dec 20, 2011 | none ahead |
| Azidus Brasilits history only | 10 open or running | phase 1since Sep 21, 2012 | Sep 21, 2012 | none ahead |
| Clinical Research Managementits history only | 10 open or running | phase 2since Mar 1, 2015 | Mar 1, 2015 | none ahead |
| Cumberland Pharmaceuticalsits history only | 10 open or running | phase 2since Jul 19, 2018 | Jul 19, 2018 | none ahead |
| Daewon Pharmaceuticalits history only | 10 open or running | phase 3since Jul 24, 2023 | Jul 24, 2023 | none ahead |
| Daewoong Pharmaceuticalits history only | 10 open or running | phase 3since Oct 26, 2016 | Oct 26, 2016 | none ahead |
| Dr. Md. Alimur Rezaits history only | 10 open or running | phase 4since Jan 17, 2025 | Jan 17, 2025 | none ahead |
| Huons Globalits history only | 11 open or running | phase 1since Aug 5, 2026 | Aug 5, 2026 | Apr 2027phase 1 · NCT07784608 |
| Intarcia Therapeuticsits history only | 10 open or running | phase 1since Dec 21, 2015 | Dec 21, 2015 | none ahead |
| Jeil Pharmaceuticalits history only | 10 open or running | phase 1since Mar 5, 2018 | Mar 5, 2018 | none ahead |
| Laboratorios Silanes S.A. de C.V.its history only | 10 open or running | phase 3since Apr 29, 2021 | Apr 29, 2021 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 10 open or running | phase 1since Sep 9, 2009 | Sep 9, 2009 | none ahead |
| Samil Pharmaceuticalits history only | 10 open or running | phase 1since Oct 13, 2015 | Oct 13, 2015 | none ahead |
Also a collaborator on its studies: Parexel, Pharma Medica Research, Merck, Regeneron Pharmaceuticals, MDS Pharma Services, Celerion, Sanofi and Basilea Pharmaceutica International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Organon only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Sep 23, 2004.
- Nov 2, 2006Phase 3 study in Cardiovascular DiseasesNCT00395603 · 550 enrolled
- Jan 3, 2007Phase 3 study in HypercholesterolemiaNCT00418834 · 1,053 enrolled
- Sep 25, 2007Phase 3 study in HypercholesterolemiaNCT00535405 · 1,289 enrolled
- Oct 5, 2007Phase 3 study in Diabetes Mellitus, Type 2NCT00541697 · 648 enrolled
- Mar 31, 2008Phase 3 study in HypercholesterolemiaNCT00650689 · 122 enrolled
- Apr 1, 2008Phase 3 study in HypercholesterolemiaNCT00654095 · 146 enrolled
- Apr 1, 2008Phase 4 study in HypercholesterolemiaNCT00653796 · 148 enrolled
- Oct 29, 2008Phase 3 study in HypercholesterolemiaNCT00782184 · 250 enrolled
- Mar 26, 2009Phase 4 study in Primary HypercholesterolemiaNCT00871351 · 125 enrolled
- Jun 29, 2010Phase 3 study in HypercholesterolemiaNCT01154036 · 1,547 enrolled
- Jun 8, 20112 phase 3 studies in HypercholesterolemiaNCT01370603, NCT01370590
- May 29, 2015Phase 3 study in HypercholesterolemiaNCT02460159 · 135 enrolled
- Sep 14, 2015Phase 3 study in HypercholesterolemiaNCT02550288 · 309 enrolled
- Mar 6, 20193 phase 3 studiesNCT03884452, NCT03867318, NCT03867110
TargetBeta
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule
Other programs on HMGCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| rosuvastatinrule | AstraZeneca | phase 4 | 184 |
| Simvastatinrule | Organon | phase 4 | 100 |
| pitavastatinrule | Kowa | phase 4 | 36 |
Studies
All 20 Organon leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03884452Hyperlipoproteinemia Type II | 3 | Completed | May 24, 2001 | 50 |
| NCT03867318Hypercholesterolemia | 3 | Completed | Nov 16, 2001 | 621 |
| NCT03867110Hypercholesterolemia | 3 | Completed | Jul 27, 2001 | 628 |
| NCT02550288Hypercholesterolemia | 3 | Completed | May 30, 2016 | 309 |
| NCT02460159Hypercholesterolemia | 3 | Completed | Dec 22, 2016 | 135 |
| NCT01370603Hypercholesterolemia | 3 | Completed | May 2012 | 328 |
| NCT01370590Hypercholesterolemia | 3 | Completed | Apr 2012 | 406 |
| NCT01154036Hypercholesterolemia | 3 | Completed | Sep 2012 | 1,547 |
| NCT00871351Primary Hypercholesterolemia | 4 | Completed | May 1, 2010 | 125 |
| NCT00782184Hypercholesterolemia | 3 | Completed | Sep 2010 | 250 |
| NCT00654095Hypercholesterolemia | 3 | Completed | Jun 1, 2009 | 146 |
| NCT00653796Hypercholesterolemia | 4 | Completed | Aug 1, 2004 | 148 |
| NCT00650689Hypercholesterolemia | 3 | Completed | Dec 2004 | 122 |
| NCT00541697Diabetes Mellitus, Type 2 | 3 | Completed | Sep 28, 2005 | 648 |
| NCT00535405Hypercholesterolemia | 3 | Completed | Mar 2009 | 1,289 |
| NCT00418834Hypercholesterolemia | 3 | Completed | Oct 2008 | 1,053 |
| NCT00395603Cardiovascular Diseases | 3 | Terminated | Jun 2007 | 550 |
| NCT00110435Diabetes Mellitus, Type 2 | 3 | Completed | Dec 2005 | 1,229 |
| NCT00092716Hypercholesterolemia | 3 | Completed | Apr 2003 | 655 |
| NCT00092690Hypercholesterolemia | 3 | Completed | Mar 2004 | 1,902 |
How it is read
Names in the registry
- “Atorvastatin”, 95 entries
- “atorvastatin”, 36 entries
- “Atorvastatin 20 mg”, 3 entries
- “Comparator: atorvastatin”, 3 entries
- “Atorvastatin 10 mg”, 3 entries
Conditions, from the studies’ own filings
- Hypercholesterolemia, 48 studies
- Dyslipidemias, 15 studies
- Hyperlipidemias, 11 studies
- Diabetes Mellitus, Type 2, 9 studies
- Cardiovascular Diseases, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.